Insulet's Trading Volume Drops 44.86% to 1.91 Billion, Stock Rises 2.13% Despite 473rd Ranking

On March 24, 2025, Insulet's trading volume reached 1.91 billion, a significant drop of 44.86% from the previous day, placing it at the 473rd position in the daily stock market rankings. The company's stock, PODD, has seen a 2.13% increase, marking two consecutive days of gains and a total increase of 3.26% over the past two days.

Insulet Corporation has experienced robust momentum over the past year, driven by the success of its innovative Omnipod 5 system and impressive market expansion. The Omnipod 5 system, which is the only FDA-cleared, fully disposable pod-based automated insulin delivery (AID) system, has significantly expanded the total addressable market for Insulet by making it commercially available to more than 5.5 million people in the United States.

Insulet's strategic market expansion efforts have also contributed to investor optimism. Following successful launches in France and the Netherlands, the company introduced Omnipod 5 in five additional countries in January 2025, including Italy, Denmark, Finland, Norway, and Sweden. In March 2025, Omnipod 5 became available in Australia. The company plans to launch Omnipod 5 in additional markets in the upcoming quarters of 2025, starting with Belgium and Switzerland, and later in Canada, Israel, Saudi Arabia, the United Arab Emirates, Qatar, and Kuwait.